Meet Laura | Pradaxa® Patient Profiles | Boehringer Ingelheim
- 79 years old
- Active grandmother…
6 grandchildren keep her busy!
- Recently diagnosed with nonvalvular
atrial fibrillation (NVAF). Her cousin takes apixaban
but Laura wants to know more about all of her
How will you counsel Laura
on her options?
Laura is interested in discussing a
lower risk of bleeding
In a real-world, observational analysis, Pradaxa® 110 mg had a lower risk of
any bleeding vs warfarin while apixaban 2.5 mg and rivaroxaban 15 mg were
associated with a similar risk vs warfarin (n=55,644)1
Not a head-to-head study; this was a real-world, observational analysis comparing the effectiveness and safety of Pradaxa® 110 mg, rivaroxaban 15 mg, and apixaban 2.5 mg vs warfarin.
Hazard ratios for additional bleeding outcomes: major bleeding=Pradaxa® 0.87 (0.75 to 1.10), apixaban 1.04 (0.76 to 1.43), rivaroxaban 1.17 (0.94 to 1.45); haemorrhagic
stroke=Pradaxa® 0.46 (0.29 to 0.72), apixaban 0.59 (0.34 to 1.02), rivaroxaban 0.68 (0.30 to 1.53).
Laura will thank you for prescribing the
most studied low-dose NOAC
Pradaxa® 110 mg has been studied in more patients than
both rivaroxaban and apixaban
If Laura ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®
Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures5
Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects5
Easy to use—1 ready-to-use dose for ALL Pradaxa® patients5
Widely available—8,300+ sites in 48 countries6
- 1. Nielsen PB et al. BMJ. 2017;356:j510.
- 2. Connolly SJ et al. N Engl J Med. 2009;361(12):1139-1151.
- 3. Fox KAA et al. Eur Heart J. 2011;32(19):2387-2394.
- 4. Granger CB et al. N Engl J Med. 2011;365(11):981-992.
- 5. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018.
- 6. Data on file, Boehringer Ingelheim.